Jefferies downgraded Marinus Pharmaceuticals (MRNS) to Hold from Buy with a price target of 50c, down from $5. The company’s Phase III study of oral ganaxolone in tuberous sclerosis complex rare-epilepsy failed to meet the primary endpoint of seizure reduction, the analyst tells investors in a research note. The firm sees no near-term catalysts in 2025, driving the downgrade to Hold.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRNS:
- Marinus Pharmaceuticals price target lowered to $3 from $23 at EF Hutton
- Marinus Pharmaceuticals price target lowered to 50c from $2 at Baird
- Marinus Pharmaceuticals downgraded to Market Perform at JMP Securities
- Marinus downgraded to Market Perform from Outperform at JMP Securities
- Marinus Pharmaceuticals downgraded to Hold from Buy at Truist